Literature DB >> 16272635

[Risedronate: a possible treatment for extraosseous calcification].

Naohiko Fujii1, Takayuki Hamano, Yoshitaka Isaka, Takahito Ito, Enyu Imai.   

Abstract

A case report of 51 year-old female, diagnosed as CREST syndrome, presenting with an ectopic calcification in the left shoulder joint, which disappeared soon after the start of risedronate. She had been taking steroid and NSAIDs for the past four years, but the pain and the range of motion of her shoulder became worse and restricted progressively during the last three years only to form extraosseous calcification. Laboratory data showed normal renal function, no inflammatory changes, and no abnormalities in calcium and and phosphate metabolism including parathyroid hormone. Risedronate was administered for glucocorticoid-induced osteoporosis. Although the bone turnover markers, such as serum NTX (N-terminal telopeptides of type I collagen) and BSAP (bone specific alkaline phosphate), did not show remarkable changes, the pain disappeared a week later and the range of motion recovered a month later. The X-ray at 6 months risedronate treatment revealed a complete disappearance of the ectopic calcification. Risedronate, probably through a different process from etidronate, could prevent extraosseous calcification.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16272635     DOI: CliCa05S-17579

Source DB:  PubMed          Journal:  Clin Calcium        ISSN: 0917-5857


  3 in total

1.  Can clodronate be effective in the treatment of disabling hydroxyapatite crystal-deposition disease? A report of two cases.

Authors:  Gianantonio Saviola; Lul Abdi-Ali; Paola Baiardi; Maurizio Benucci
Journal:  Rheumatol Int       Date:  2010-07-28       Impact factor: 2.631

Review 2.  Subcutaneous calcinosis: Is it different between systemic sclerosis and dermatomyositis?

Authors:  Antonia Valenzuela; Lorinda Chung
Journal:  J Scleroderma Relat Disord       Date:  2021-10-28

3.  Calcinosis is associated with digital ulcers and osteoporosis in patients with systemic sclerosis: A Scleroderma Clinical Trials Consortium study.

Authors:  Antonia Valenzuela; Murray Baron; Ariane L Herrick; Susanna Proudman; Wendy Stevens; Tatiana S Rodriguez-Reyna; Alessandra Vacca; Thomas A Medsger; Monique Hinchcliff; Vivien Hsu; Joy Y Wu; David Fiorentino; Lorinda Chung
Journal:  Semin Arthritis Rheum       Date:  2016-06-02       Impact factor: 5.532

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.